EDIT Editas Medicine, Inc.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001650664
AI RATING
SELL
65% Confidence

Investment Thesis

Editas is a pre-commercial biotech burning $23M annually with minimal $2.8M revenue and unsustainably high debt-to-equity of 10.70x relative to its $4.4M equity base. While the $123.6M cash position provides 5+ years of runway, the combination of severe operating losses, negative cash flows, and excessive leverage creates significant downside risk without demonstrated clinical or commercial progress.

Strengths

  • + Strong absolute cash position of $123.6M provides runway for R&D execution
  • + Revenue growing 25.4% YoY demonstrates some market traction despite small base
  • + Current liquidity ratios (3.22x) are healthy with minimal short-term solvency risk

Risks

  • ! Debt-to-equity ratio of 10.70x is dangerously high for an unprofitable company with only $4.4M equity
  • ! Operating cash burn of $23.1M annually is unsustainable relative to $2.8M revenue with no profitability timeline visible
  • ! Extreme negative margins (-882% net margin) and dependence on R&D outcomes create execution risk with no near-term path to profitability

Key Metrics to Watch

Financial Metrics

Revenue
2.8M
Net Income
-25.0M
EPS (Diluted)
$-0.26
Free Cash Flow
-23.2M
Total Assets
149.3M
Cash
123.6M

Profitability Ratios

Gross Margin N/A
Operating Margin -883.2%
Net Margin -882.4%
ROE -566.7%
ROA -16.7%
FCF Margin -817.8%

Balance Sheet & Liquidity

Current Ratio
3.22x
Quick Ratio
3.22x
Debt/Equity
10.70x
Debt/Assets
97.0%
Interest Coverage
-23.32x
Long-term Debt
47.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T08:18:30.801185 | Data as of: 2026-03-31 | Powered by Claude AI